Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6785352rdf:typepubmed:Citationlld:pubmed
pubmed-article:6785352lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0019764lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C1513095lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0017968lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:6785352lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:6785352pubmed:issue6lld:pubmed
pubmed-article:6785352pubmed:dateCreated1981-7-23lld:pubmed
pubmed-article:6785352pubmed:abstractTextHuman malignant melanoma cell line SK-MEL-37 expresses HLA-DR antigens having a characteristic 2-chain structure, with heavy chains (alpha) of approximately 32,000 daltons and light chains (beta) of approximately 28,000 daltons. Nonequilibrium pH-gradient electrophoresis (NEPHGE) on HLA-DR immunoprecipitated by rabbit anti-HLA-DR sera from [35S]-methionine-labeled, pulse-chased cells showed 2 closely spaced heavy-chain components (1, 2) and 4 light-chain spots (3-6). From nonchased samples, numerous more-basic components running in the heavy chain region were also precipitated. In particular, a very basic, 30,000 dalton component (pl approximately 8.5) was prominent (component 7); this spot probably corresponds to the invariant (Ii) peptide previously demonstrated in lymphoid cell HLA-DR precipitates (9) and the M-1 peptide of Shackelford and Strominger (10). None of these components (alpha, beta, or component 7) was precipitated from extracts of HLA-DR-negative melanoma cells. Pulse-chase experiments and the use of different labeled sugar precursors showed that component 7 is a partially glycosylated intracellular precursor, possibly of the HLA-DR alpha-chain. None of the immunoprecipitates, even from cells pulse-labeled for only 15 min, contained a peptide migrating in the 55,000 to 60,000 m.w. region. It was concluded that melanoma HLA-DR is not synthesized via a polyprotein precursor. In contrast to these results, obtained with rabbit anti-HLA-DR sera, a mouse monoclonal anti-HLA-DR was found to precipitate only biosynthetically completed alpha (1, 2) and beta (3-6) chains.lld:pubmed
pubmed-article:6785352pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:languageenglld:pubmed
pubmed-article:6785352pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6785352pubmed:statusMEDLINElld:pubmed
pubmed-article:6785352pubmed:monthJunlld:pubmed
pubmed-article:6785352pubmed:issn0022-1767lld:pubmed
pubmed-article:6785352pubmed:authorpubmed-author:LloydK OKOlld:pubmed
pubmed-article:6785352pubmed:authorpubmed-author:NgJJlld:pubmed
pubmed-article:6785352pubmed:authorpubmed-author:DippoldW GWGlld:pubmed
pubmed-article:6785352pubmed:issnTypePrintlld:pubmed
pubmed-article:6785352pubmed:volume126lld:pubmed
pubmed-article:6785352pubmed:ownerNLMlld:pubmed
pubmed-article:6785352pubmed:authorsCompleteYlld:pubmed
pubmed-article:6785352pubmed:pagination2408-13lld:pubmed
pubmed-article:6785352pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:meshHeadingpubmed-meshheading:6785352-...lld:pubmed
pubmed-article:6785352pubmed:year1981lld:pubmed
pubmed-article:6785352pubmed:articleTitleAnalysis of the biosynthesis of HLA-DR glycoproteins in human malignant melanoma cell lines.lld:pubmed
pubmed-article:6785352pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6785352pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6785352lld:pubmed